Erratum in: “Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury” by Lycia Pedral Sampaio, Guilherme S. L. Hilgert, Thomas Michael Shiju, Marcony R. Santhiago, and Steven E. Wilson (
Transl Vis Sci Technol. 2022;11(7):9),
https://doi.org/10.1167/tvst.11.7.9.
The authors discovered that the stock medication used in preparation of the topical 0.8% losartan in balanced salt solution for this study contained “excipients” used in the manufacture of losartan tablets. As a result, the true final concentration was 0.2% losartan in the balanced salt solution used for the topical application of losartan in this study; 0.8 mg/mL losartan has now been changed to 0.2 mg/mL losartan throughout the article online.